Saroglitazar Demonstrates Efficacy in Primary Biliary Cholangitis Topline data were announced from a phase 2b/3 trial evaluating saroglitazar in patients with PBC who had an inadequate response or intolerance to UDCA.

Statistically significantly greater proportion of #saroglitazar-treated patients achieved a biochemical response vs placebo.

Read More: https://bit.ly/47TXumO

Zydus Therapeutics Achieves Encouraging Results in Saroglitazar Trial for Liver Disease Treatment Zydus Therapeutics has reported promising findings from their EPICS-III trial of Saroglitazar, a novel treatment for Primary Biliary Cholangitis. This news brings hope to many patients in need.

Zydus Therapeutics Achieves Encouraging Results in Saroglitazar Trial for Liver Disease Treatment #USA #Zydus_Lifesciences #Pennington #Saroglitazar #PBC

🚀 Delta4 secures European #patents for two FSGS-targeting compounds: #Clopidogrel (reduces kidney damage) & #Saroglitazar + #Myristic Acid (improve pathology). AI-driven Drug Discovery at its best! Read more on this development and its background: buff.ly/c3KiAkh

#Delta4 #FSGS #Treatment #Medicine

@AASLDtweets dr. Gawrieh: #saroglitazar (PPAR-alpha, gamma) reduces ALT as early as week 4 and about 40% reduce MRI-PDFF by >30% at highest dose. I would really like to get excited about PPARs in #NASH but I can’t. #LiverMtg19